Brief: Chemomab Therapeutics And AGC Biologics Expand Partnership
23/06/2021 13:43
June 23 (Reuters) - Chemomab Therapeutics Ltd CMMB.O :
* CHEMOMAB THERAPEUTICS AND AGC BIOLOGICS EXPAND PARTNERSHIP
TO
MANUFACTURE CM-101 FOR PHASE II/III
* CHEMOMAB THERAPEUTICS - AGC BIOLOGICS TO MANUFACTURE
CLINICAL
TRIAL MATERIALS AT COPENHAGEN SITE
Source text for Eikon: ID:nGNX3r8WpJ
Further company coverage: CMMB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Chemomab Therapeutics
See all newsBrief: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results And Provides Corporate Update
Chemomab Therapeutics Ltd expected to post a loss of 15 cents a share - Earnings Preview
Israel's Chemomab Q4 net loss narrows on lower R&D spend
Brief: Chemomab Therapeutics Announces Nebokitug Phase 2 Spring Trial Results
Brief: Chemomab Therapeutics Announces Third Quarter 2025 Financial Results And Provides Corporate Update